Originally Published as The Niche Podcast

Vaccines are here, capitalizing on capital with IPOs, and Gilead targets Hepatitis D.



Sponsors
https://www.thescopemethod.com


Story References
https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19
https://www.abcellera.com/news/2020-12-10-abcellera-announces-pricing-of-ipo
https://www.certara.com/pressrelease/certara-announces-pricing-of-its-upsized-initial-public-offering/
https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4d-molecular-therapeutics-announces-upsized-pricing-initial
https://www.nanobiotix.com/wp-content/uploads/2020/12/PR-Pricing.pdf
https://www.gilead.com/news-and-press/press-room/press-releases/2020/12/gilead-sciences-to-acquire-myr-gmbh


Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

 
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.